CYTK

Cytokinetics, Inc. is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle biology-directed drug candidates. The company's research and development programs target diseases where muscle performance is compromised including heart failure, amyotrophic lateral sclerosis (ALS), and other neuromuscular conditions. Cytokinetics has multiple clinical-stage candidates that modulate muscle contractility through novel mechanisms of action. The company collaborates with major pharmaceutical partners and has advanced several product candidates into late-stage clinical trials.